A First-in-Human Study of CD123 Natural Killer Cell Engager (NKCE) SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-Myelodysplasia (HR-MDS)

被引：0
|
作者：
Stein, Anthony [1 ]
Lavrencic, Mojca [2 ]
Garciaz, Sylvain [3 ]
Huls, Gerwin [4 ]
Maiti, Abhishek [5 ]
Boissel, Nicolas [6 ]
Botton, Stephane [7 ]
Fleming, Shaun [8 ]
Zwaan, Michel [9 ]
de Leeuw, David C. [10 ]
Desai, Pinkal [11 ]
Arellano, Martha [12 ]
Avigan, David [13 ]
Langemeijer, Saskia [14 ]
Jensen, Kyle [15 ]
Wagenaar, Timothy [15 ]
Mi Gu [15 ]
Abbadessa, Giovanni [15 ]
Bajel, Ashish [16 ,17 ]
机构：
[1] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA
[2] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
[3] Aix Marseille Univ, Inst Paoli Calmettes, Marseille, France
[4] Univ Med Ctr Groningen, Groningen, Netherlands
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Hop St Louis, Paris, France
[7] Inst Gustave Roussy, Paris, France
[8] Alfred Hlth, Melbourne, Vic, Australia
[9] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands
[10] Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
[11] Weill Cornell Med, New York, NY USA
[12] Emory Univ, Atlanta, GA 30322 USA
[13] Beth Israel Deaconess Med Ctr, Boston, MA USA
[14] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands
[15] Sanofi, Cambridge, MA USA
[16] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[17] Royal Melbourne Hosp, Melbourne, Vic, Australia
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2023年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P-002
引用
收藏
页码：S3 / S4
页数：2
相关论文
共 50 条
  • [31] Real-World Outcomes of Brexucabtagene Autoleucel ( brexu-cel) for Relapsed or Refractory (R/R) Adult B-Cell Acute Lymphoblastic Leukemia (B-cell ALL): Evidence from the CIBMTR Registry
    Bezerra, Evandro
    Itani, Taha
    Wudhikarn, Kistada
    Perales, Miguel-Angel
    Yang, Yang
    Gergis, Usama
    Aribi, Ahmed
    Hill, LaQuisa C.
    Jain, Nitin
    Leonard, Jessica T.
    Lutfi, Forat
    Kim, Soyoung
    Bye, Matthew
    Wang, Hai-Lin
    Hadjivassileva, Tsveta
    Nikolaenko, Liana
    Kloos, Ioana
    Abdeldaim, Amina
    Dalton, David
    Xu, Hairong
    Pasquini, Marcelo
    Kebriaei, Partow
    BLOOD, 2023, 142
  • [32] The Prognostic Value of Minimal Residual Disease (MRD) after Salvage Therapy in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL)
    Yilmaz, Musa
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Jorgensen, Jeffrey L.
    Wang, Sa
    Garcia-Manero, Guillermo
    Cortes, Jorge E.
    Sasaki, Koji
    DiNardo, Courtney
    Kadia, Tapan
    Autry, Jane
    Garris, Rebecca
    Jabbour, Elias
    BLOOD, 2015, 126 (23)
  • [33] Long-term survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3
    Oluwole, Olalekan O.
    Ghobadi, Armin
    Cassaday, Ryan Daniel
    Park, Jae H.
    Houot, Roch
    Logan, Aaron
    Boissel, Nicolas
    Leguay, Thibaut
    Bishop, Michael Russell
    Topp, Max S.
    O'Dwyer, Kristen M.
    Baer, Maria R.
    Schiller, Gary J.
    Abedi, Mehrdad
    Minnema, Monique C.
    Stiff, Patrick J.
    Zhou, Lang
    Siddiqi, Rubina
    Khalid, Rita Damico
    Shah, Bijal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Evolution of tisagenlecleucel use for the treatment of pediatric and young adult relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL): Center for International Blood & Marrow Transplant Research (CIBMTR) registry results
    Rouce, Rayne H.
    Baumeister, Susanne H. C.
    Curran, Kevin J.
    Fabrizio, Vanessa A.
    Hall, Erin M.
    Hsieh, Emily M.
    Karras, Nicole A.
    Keating, Amy K.
    Moskop, Amy
    Pasquini, Marcelo C.
    Phillips, Christine L.
    Pulsipher, Michael A.
    Nuortti, Marja
    Willert, Jennifer
    Ramos, Roberto
    John, Samuel
    Grupp, Stephan A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] Evolution of Tisagenlecleucel Use for the Treatment of Pediatric and Young Adult Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Center for International Blood & Marrow Transplant Research (CIBMTR) Registry Results
    Rouce, Rayne H.
    Baumeister, Susanne H. C.
    Curran, Kevin J.
    Fabrizio, Vanessa A.
    Hall, Erin M.
    Hsieh, Emily M.
    Karras, Nicole A.
    Keating, Amy K.
    Moskop, Amy
    Pasquini, Marcelo C.
    Phillips, Christine L.
    Pulsipher, Michael A.
    Nuortti, Marja
    Willert, Jennifer
    Ramos, Roberto
    John, Samuel
    Grupp, Stephan A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S261 - S262
  • [36] BAFF Receptor (BAFF-R) Car-Redirected T Cells as a Novel Tool to Treat High Risk B-Cell Acute Lymphoblastic Leukemia (B-ALL)
    Turazzi, N.
    Fazio, G.
    Rossi, V.
    Rolink, A.
    Cazzaniga, G.
    Biondi, A.
    Magnani, C. F.
    Biagi, E.
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S54 - S54
  • [37] Significant Long-Term Benefits of CAR T-Cell Therapy Followed By a Second Allo-HSCT for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Who Relapsed after an Initial Transplant
    Zhang, Jianping
    Yang, Junfang
    Zhang, Xian
    Li, Jingjing
    Cao, Xingyu
    Zhao, Yanli
    Wei, Zhijie
    Liu, Deyan
    Xiong, Min
    Lu, Yue
    Zhou, Jiarui
    Sun, Ruijuan
    Lu, Peihua
    BLOOD, 2020, 136
  • [38] OUTCOME OF REINDUCTION CHEMOTHERAPY FOR CHILDREN WITH RELAPSED B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA; RESULTS OF THE JPLSG ALL-R14 STUDY
    Goto, Hiroaki
    Kada, Akiko
    Sakaguchi, Kimiyoshi
    Ueki, Hideaki
    Toyoda, Hidemi
    PEDIATRIC BLOOD & CANCER, 2022, 69
  • [39] Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy Targeting CD19 and CD22, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study
    Amrolia, Persis J.
    Wynn, Robert
    Hough, Rachael E.
    Vora, Ajay
    Bonney, Denise
    Veys, Paul
    Chiesa, Robert
    Rao, Kanchan
    Clark, Liz
    Al-Hajj, Muhammad
    Cordoba, Shaun P.
    Onuoha, Shimobi
    Kotsopoulou, Ekaterini
    Khokhar, Nushmia Z.
    Pule, Martin
    Peddareddigari, Vijay G. R.
    BLOOD, 2019, 134
  • [40] ZUMA-4 Phase 1: KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Children and Adolescents with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)
    Wayne, A. S.
    Huynh, V.
    Hijiya, N.
    Rouce, R.
    Brown, P. A.
    Krueger, J.
    Rytting, M.
    Kitko, C. L.
    Dela Ziga, E.
    Hermiston, M.
    Richards, M. K.
    Baruchel, A.
    Mardiros, A.
    Shen, T.
    Goyal, L.
    Vezan, R.
    Jain, R.
    Lee, D. W.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S7 - S7
12345